Frontlight ResearchEarly access
CompletedNo phase
Exploratory Study of SAT-001 in Treatment of Pediatric Patient With Myopia
Key facts
- Who runs it
- S-Alpha Therapeutics, Inc.
- Where
- South Korea6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 5 Mar 2021
- Ended
- 3 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- SAT-001(Software as Medical Device)
- Record updated
- 3 May 2024
Who can take part
- Age
- 5 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Pediatric patient age 5 to 12 years old at the Screening Visit
- Diagnosed with myopia as following refractive error via cycloplegic refraction(CR); Spherical equivalent (SE) -0.75 D or more and less than -6.00 D in each eye; Astigmatism of 1.50 D or less in each eye; Anisometropia of less than 1.00 D
- The age of birth over 38 weeks
- Over 2500g of birth weight
- Best corrected distance visual acuity of 0.2 logMAR or better in each eye at the Screening Visit
- Intraocular pressure 21 mmHg or less in each eye at the Screening Visit
Who cannot take part
- Administration of anti-muscarine drugs within 1 month before screening visit
- Current or previous use of multi-focal lenses
- History of atropine use for treatment of myopia within 1 month before screening visit
- Participation in another clinical trial within 6 months before screening visit
- History of growth hormone treatment within 1 month before screening visit
- Currently taking or having taken antihistamines (tablets, nasal spray, eye drops, etc.) or psychiatric drugs (antidepressants, anti-anxiety medications, etc.) within 30 days before screening visit
- History of injections with histamine release and cholinergic effect within 30 days before screening visit
- Abnormal conditions in cornea, lens, central retina, iris and ciliary bodies or malignant tumors around orbit
- History of manifest strabismus, intermittent strabismus, amblyopia, nystagmus etc. (except for phoria maintaining binocular vision)
- History of ophthalmic surgery, such as eyelid surgery, strabismus surgery, intraocular surgery, or refractive correction surgery (except for epiblepharon surgery)
- Obsessive-compulsive disorder or attention deficit hyperactivity disorder(ADHD)
- Down's syndrome or cerebral palsy
- Significant systemic diseases such as congenital heart disease, respiratory system disease (except for asthma), endocrine disease or nervous system disease
- Planning to use or having used Orthokeratology lenses (Ortho-K lenses), Rigid Gas Permeable (RGP) lenses, and other contact lenses to reduce the progression of myopia
- Medically clear to have abnormal range of intellectual development
- Incongruent to participate in this study at the discretion of the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The Purpose of this study is to explore the safety and effectiveness of SAT-001, a medical device for the treatment of myopia in pediatric patient with myopia
The 2 groups in the trial
- SAT-001Treatment being tested
Treatment: SAT-001(Software as Medical Device)
- Control GroupNo study treatment, for comparison
Wearing glasses or not
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised, Open-label, Multicenter, Controlled, Exploratory Study on the Effect and Safety of SAT-001 as a Medical Device in Treatment of Pediatric Patients With Myopia
- Record updated
- 3 May 2024